Earnings · China A-shares
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A (688505) earnings
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A published its Q3 report on 2026-10-29: net profit +341.02% year on year, +149.69% excluding one-off items. Wave Radar's earnings-quality score is 82 of 100 (Sound). The stock moved -4.05% in the 3 trading days after the report.
- Report
- Q3 report
- Published
- 2026-10-29
- Period end
- 2026-09-30
- Net profit YoY
- +341.02%
- Excl. one-offs YoY
- +149.69%
- Net profit QoQ
- -94.81%
- Result
- Great
- Quality score
- 82
- Quality
- Sound
Stock move after the report
Trading days from the first tradeable session; dividend-adjusted. "vs index" is the excess return over CSI 300 for A-shares.
| After | Return | vs index |
|---|---|---|
| 1 day | -3.07% | — |
| 3 days | -4.05% | — |
| 7 days | -1.82% | — |
| 14 days | -8.24% | — |
Report history
Over the last 8 reports, net profit grew year on year in 4 of them. The stock rose in the 3 trading days after 4 of 8 reports (average +0.81%).
| Report | Published | Net profit | Profit YoY | Excl. one-offs YoY | Revenue YoY | EPS | ROE | 3 days after | 30 days after | 30d vs index |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026 Q3 report | 2026-10-30 | ¥38.41M | +341.02% | +149.69% | -3.88% | 0.04 | 1.80% | -4.05% | — | — |
| 2026 interim report | 2026-08-15 | ¥36.89M | +545.57% | +328.60% | -4.58% | 0.04 | 1.73% | -0.70% | -3.38% | +3.22% |
| 2026 Q1 report | 2026-04-30 | ¥7.71M | +189.36% | +3.29% | -17.15% | 0.01 | 0.36% | +3.48% | -12.39% | -14.44% |
| 2025 annual report | 2026-03-31 | -¥157.44M | -496.23% | — | -3.33% | -0.15 | -7.12% | +2.49% | -2.99% | -11.40% |
| 2025 Q3 report | 2025-10-31 | -¥15.94M | -118.43% | — | +0.41% | -0.02 | -0.70% | -0.11% | -9.49% | -4.80% |
| 2025 interim report | 2025-08-13 | ¥5.72M | -91.89% | — | -4.42% | 0.01 | 0.25% | -0.48% | -13.69% | -22.88% |
| 2025 Q1 report | 2025-04-29 | ¥2.67M | +13.53% | +26.82% | +21.85% | 0.00 | 0.12% | +4.22% | +13.46% | +10.88% |
| 2024 annual report | 2025-03-28 | ¥39.73M | -63.42% | -92.64% | -16.61% | 0.04 | 1.70% | +1.59% | -4.03% | -2.94% |
The last 8 reports. Net profit is attributable to shareholders and year-to-date (a Q3 report covers the first nine months). Moves count trading days from the first tradeable session after publication; "30d vs index" is the excess return over CSI 300.
How to read this
Results are grouped by reported profit growth (great, good, neutral, bad or a loss). For China A-shares the quality score starts at 100 and loses points for gaps a reader can check: operating cash falling short of profit, receivables or inventory outrunning revenue, profit that rests on one-off items or subsidies, heavy goodwill and a qualified audit opinion.
Figures are generated automatically from Wave Radar's published market data and refresh after each market close.